VRK1 and lung carcinoma: Although UA itself might not be sufficient for specific VRK1 inhibition in vivo, employing de novo structure-based drug design methods or fragment-based approaches at the interacting residues with UA or exploiting structural analogs of UA could facilitate development of novel drugs for the treatment of lung cancer, with minimal side effects.